Epizyme (EPZM -1%) comes out of the quiet period with a number of firms initiating coverage...

|About: Epizyme (EPZM)|By:, SA News Editor

Epizyme (EPZM -1%) comes out of the quiet period with a number of firms initiating coverage today: JMP Securities with a Buy and a $40 price target, Leerink Swann and Cowen both with an Outperform, and Citigroup with a Buy rating.